

PRIOR AUTHORIZATION CRITERIA

DRUG CLASS PANCREATIC ENZYMES

BRAND NAME
(generic)

CREON
(pancrelipase)

PANCREAZE
(pancrelipase)

PERTZYE
(pancrelipase)

VIOKACE
(pancrelipase)

ZENPEP
(pancrelipase)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization

FDA-APPROVED INDICATIONS

Creon

Creon (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Pancreaze, Pertzye, Zenpep

Pancreaze, Pertzye, and Zenpep (pancrelipase) are indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Viokace

Viokace (pancrelipase) tablets, in combination with a proton pump inhibitor, is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions
AND
- If the request is for Viokace, the patient will take with a proton pump inhibitor (PPI)

REFERENCES

1. Creon [package insert]. North Chicago, IL: AbbVie Inc.; June 2022.
2. Pancreaze [package insert]. Campbell, CA: Vivus, Inc.; January 2022.
3. Pertzye [package insert]. Bethlehem, PA: Digestive Care, Inc.; March 2020.

4. Viokace [package insert]. Madison, NJ: Allergan USA, Inc.; March 2020.
5. Zenpep [package insert]. Madison, NJ: Allergan USA, Inc.; March 2020.
6. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2022; Accessed July 29, 2022.
7. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed July 29, 2022.